EICHOR
● Recruiting
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Condition: Solid Malignancies · Hematologic Malignancies · Sponsor: Immunome, Inc.
About this study
IM-1021-101 is a Phase 1 study to determine the safety and effectiveness of IM-1021 in treating participants with advanced cancer.
This description comes directly from the study's public registry record.
Talk to the study team
Immunome Medical Monitor · 425.939.7410 · info@immunome.com
Always discuss trial participation with your own doctor first.
Locations (24)
| City Of Hope | Duarte, California, United States | Recruiting |
| University of California | Los Angeles, California, United States | Recruiting |
| Colorado Blood Cancer Institute | Denver, Colorado, United States | Recruiting |
| Yale University Medical Center | New Haven, Connecticut, United States | Recruiting |
| Tampa General Hospital | Tampa, Florida, United States | Recruiting |
| Emory Winship Cancer Institute | Atlanta, Georgia, United States | Recruiting |
| University of Iowa | Iowa City, Iowa, United States | Recruiting |
| Norton Cancer Institute | Louisville, Kentucky, United States | Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Recruiting |
| START Midwest | Grand Rapids, Michigan, United States | Recruiting |
| University of Nebraska Medical Center | Omaha, Nebraska, United States | Recruiting |
| Levine Cancer Institute | Charlotte, North Carolina, United States | Recruiting |
+ 12 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06823167